Liquidia (LQDA) to Release Quarterly Earnings on Monday

Liquidia (NASDAQ:LQDA) is scheduled to be announcing its earnings results before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. On average, analysts expect Liquidia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Liquidia Trading Down 1.1 %

Liquidia stock traded down $0.11 during mid-day trading on Tuesday, hitting $10.35. The company’s stock had a trading volume of 626,034 shares, compared to its average volume of 984,083. Liquidia has a 1 year low of $6.06 and a 1 year high of $16.99. The stock’s fifty day moving average is $10.31 and its two-hundred day moving average is $11.61. The firm has a market capitalization of $794.78 million, a PE ratio of -6.57 and a beta of 0.21.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LQDA. Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Bank of America cut their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 target price on shares of Liquidia in a research report on Monday, August 19th. BTIG Research cut their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Finally, Scotiabank began coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the transaction, the chief executive officer now directly owns 812,193 shares in the company, valued at $9,023,464.23. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Liquidia news, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the transaction, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at approximately $9,023,464.23. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock worth $236,021 in the last ninety days. Insiders own 30.10% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).